Ceftazidime/avibactam, sold under the brand name Avycaz among others, is a fixed-dose combination medication composed of ceftazidime, a cephalosporin antibiotic, and avibactam, a β-lactamase inhibitor. It is used to treat complicated intra-abdominal infections, urinary tract infections, and pneumonia. It is only recommended when other options are not appropriate. It is given by injection into a vein.Common side effect include nausea, fever, liver problems, headache, trouble sleeping, and pain at the site of injection. Severe side effects may include anaphylaxis, seizures, and Clostridioides difficile-associated diarrhea. While use appears to be safe in pregnancy the medication has not been well studied in this group. Doses should be adjusted in those with kidney problems. Ceftazidime works by interfering with the building of the bacterial cell wall while avibactam works by preventing ceftazidimes breakdown.The combination was approved for medical use in the United States and the European Union in 2015. It is on the World Health Organizations List of Essential Medicines. Resistances are increasingly been reported with United States, Greece and Italy accounting for 80% of cases. Medical use
Ceftazidime/avibactam is used to treat certain multidrug-resistant gram-negative infections.Ceftazidime/avibactam is used for the treatment of:

complicated intra-abdominal infections. In these cases it is often used in combination with metronidazole, which provides coverage for anaerobic pathogens. complicated urinary tract infections, including acute pyelonephritis, in adults. hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Bacterial activity
For many bacterial infections, it offers little or no advantage over ceftazidime monotherapy, due to the widespread expression of resistance mechanisms other than β-lactamase production.
Drug Information Portal. U.S. National Library of Medicine.